33 Results for "

small interfering RNA

" in MedChemExpress (MCE) Product Catalog:
Products (33)

33 Results for "small interfering RNA" in MCE Product Catalog:

Cat. No.: HY-153483
CAS No.: 1337968-84-9
Synonyms: SYL040012
Research Areas:  

Others

Bamosiran is a small interfering RNA targeting β-adrenergic receptor 2, and is used to lower intraocular pressure
loading...
    loading...
Cat. No.: HY-145638
CAS No.: 2538784-48-2
Synonyms: RO7445482
Target:  

HBV

Research Areas:  

Infection

Xalnesiran (RO7445482) is a small interfering RNA molecule that targets a conserved region of the
hepatitis B virus (HBV) genome. Xalnesiran can be used for the research of chronic hepatitis B infection .
loading...
    loading...
Cat. No.: HY-177640A
CAS No.: 2766131-24-0
Synonyms: LY3819469 sodium
Lepodisiran (LY3819469) sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-177669
CAS No.: 3061406-99-0
Synonyms: RBD4059
Vortosiran (RBD4059) is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran exhibits antithrombotic activity without impairing hemostatic function. Vortosiran can be used in research related to intravascular thrombosis .
loading...
    loading...
Cat. No.: HY-177669A
Synonyms: RBD4059 sodium
Vortosiran (RBD4059) sodium is a siRNA that inhibits the synthesis of coagulation factor XI (FXI). Vortosiran sodium shows potent inhibitory activity against mouse FXI transcripts with an IC50 of 69 pM; it exerts similar effects on common FXI transcripts from humans and monkeys, with an IC50 of 59 pM. Vortosiran sodium exhibits antithrombotic activity without impairing hemostatic function. Vortosiran sodium can be used in research related to intravascular thrombosis .
loading...
    loading...
Cat. No.: HY-145649A
CAS No.: 2380166-34-5
Synonyms: AD-85481 sodium; ALN-AGT sodium
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension .
loading...
    loading...
Cat. No.: HY-171786
CAS No.: 2928619-86-5
Target:  

CDK

Research Areas:  

Cancer

CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-153483A
Synonyms: SYL040012 sodium
Research Areas:  

Others

Bamosiran sodium is a small interfering RNA targeting β-adrenergic receptor 2, and is used to lower intraocular pressure
loading...
    loading...
Cat. No.: HY-164970
Research Areas:  

Others

TANGO1-L Human scramble negative control is the scrambled negative control for TANGO1-L small interfering RNA.
loading...
    loading...
Cat. No.: HY-138271
CAS No.: 1494676-74-2
Target:  

Phosphatase

Research Areas:  

Others

LH65.3 is a compound with the potential to modulate bacterial infection that was identified through integrated small interfering RNA and small molecule screening to control bacterial infection, involving the regulation of multiple kinases and phosphatases.
loading...
    loading...
Cat. No.: HY-147262D
Unconjugated/naked Etedesiran (without SMCC linker) is a small interfering RNA (siRNA) targeting DMPK, and also represents the unconjugated, non-SMCC linker-bound component of delpacibart etedesiran. Unconjugated/naked Etedesiran (without SMCC linker) corrects pathogenic mRNA aberrant splicing by targeting and degrading mutant DMPK mRNA, thereby releasing sequestered MBNL splicing factors. Unconjugated/naked Etedesiran (without SMCC linker) can be used in studies of myotonic dystrophy type 1 .
loading...
    loading...
Cat. No.: HY-177640C
FAM labled Lepodisiran (LY3819469) sodiumis a FAM labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...
Cat. No.: HY-177640D
Cy3 labled Lepodisiran (LY3819469) sodium is a Cy3 labled Lepodisiran sodium. Lepodisiran sodium is a GalNAc-conjugated small interfering RNA lipid-lowering agent. Lepodisiran sodium targets the hepatic LPA gene and degrades apolipoprotein (a) mRNA to silence its expression, thereby effectively reducing the production of apolipoprotein (a) and serum lipoprotein (a) in a dose-dependent manner. Lepodisiran sodium can be used in studies related to atherosclerotic cardiovascular disease .
loading...
    loading...